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Are low doses of caffeine as ergogenic as higher doses? A critical review highlighting the need for 29 
comparison to current best practice in caffeine research. 30 
 31 
Abstract 32 
 33 
Caffeine is a popular and widely utilised sporting ergogenic aid. Over the years, the effects of different caffeine 34 
doses have been researched, with the general consensus being that 3-6 mg/kg of caffeine represents the optimal 35 
caffeine dose for most people. Recently there has been increased attention placed on lower (≤3 mg/kg) caffeine 36 
doses, with some research suggesting these doses are also ergogenic. However, a critical consideration for 37 
athletes is not merely whether caffeine is ergogenic at a given dose, but whether the consumed dose provides an 38 
optimised performance benefit. Following this logic, we identify a potential oversight in the current research 39 
relating to the efficacy of lower caffeine doses. Although low caffeine doses do appear to bestow ergogenic 40 
effects, these effects have not been adequately compared to the currently accepted best practice dose of 3-6 41 
mg/kg. This methodological oversight limits the practical conclusions we can extract from the research into the 42 
efficacy of lower doses of caffeine, as the relative ergogenic benefits between low and recommended doses 43 
remains unclear. Here, we examine existing research with a critical eye, and provide recommendations both for 44 
those looking to utilise caffeine to enhance their performance, and those conducting research into caffeine and 45 
sport.  46 
 47 
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 60 
1. Introduction 61 
 62 
Of all sporting ergogenic aids, caffeine (1,3,7-trimethylxanthine) is the most popular, with 63 
approximately 75% of athletes consuming it either before or during competition [1,2]. Indeed, caffeine has such 64 
a reliable performance enhancing effect that, for over twenty years (1984-2004), high doses were banned for 65 
within-competition use by the World Anti-Doping Agency (WADA), and caffeine remains on their active 66 
monitoring programme to this day. The ergogenic effects of caffeine ingestion have been demonstrated across a 67 
wide range of sports, including endurance [3] and team sports [4], and across different exercise methods and 68 
modalities, including repeated high-intensity efforts [5], muscular endurance [6], maximum strength [7] and 69 
anaerobic performance [8].  70 
 71 
Whilst the ergogenic effects of caffeine have been known for over 100 years [9], the broad array of 72 
potential mechanisms by which caffeine exerts its performance enhancing effects have only more recently been 73 
more fully elucidated. The most well-established mechanism is that of caffeine’s role as a competitive adenosine 74 
receptor antagonist [10], dampening adenosine’s downregulation of Central Nervous System arousal [11]. In 75 
turn, this promotes the release of a spectrum of neuro-chemicals, including dopamine and the excitatory 76 
neurotransmitter glutamate [12], thereby increasing muscle firing rates [13]. Caffeine also stimulates adrenaline 77 
secretion [14], alters substrate utilization and metabolism [15], and increases cellular ion release [16]. More 78 
recently, the relationship between caffeine, pain, and exercise performance has been explored, with current 79 
evidence suggesting that caffeine decreases pain perception, which in turn reduces rating of perceived exertion 80 
(RPE) [17] and enhances exercise capacity [18]. Latterly, it has been proposed that caffeine’s bitter taste may 81 
drive some of its performance enhancing benefits [19], in a similar fashion to the documented effects of the 82 
bitter tasting compound quinine [20]; such observations may explain the ergogenic effects of caffeine-infused 83 
mouth-rinses [21]. 84 
 85 
Given that caffeine’s effects have been extensively researched, and consistently, reliably and 86 
repeatedly demonstrated to improve—and only very rarely shown to harm [22]—exercise performance, it’s use 87 
is pervasive amongst both professional and amateur athletes alike [1,2]. This extensive use has resulted in the 88 
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formulation of best practice guidelines by numerous professional bodies. The International Society of Sports 89 
Nutrition’s position stand on caffeine [23], for example, summarizes that caffeine is effective at enhancing 90 
performance at dosages considered to be moderate (~3-6 mg/kg), consumed approximately 60 minutes prior to 91 
performance, with no additional ergogenic effects seen with higher caffeine doses (>9 mg/kg). Such 92 
recommendations have been echoed elsewhere, both in the scientific literature [14,16] and lay press. 93 
Interestingly, however, a number of studies have recently shown that lower doses of caffeine, typically of ≤3 94 
mg/kg, are also ergogenic [24]. In this article, we examine the evidence underpinning this finding, and explore 95 
whether low doses (≤3 mg/kg) of caffeine pre-exercise offer comparable ergogenic benefits to the more 96 
conventionally recommended intakes (3-6 mg/kg); such an examination is crucial, as athletes are likely 97 
interested in whether their caffeine dose offers the maximal ergogenic benefits, as opposed to just an ergogenic 98 
effect. Finally, we note some methodological recommendations that researchers may wish to consider when 99 
conducting low dose caffeine research in the future.  100 
 101 
2. Are low doses of caffeine ergogenic? 102 
 103 
 Whilst, historically, high doses (up to 13 mg/kg) of caffeine have been used to induce ergogenic effects 104 
[25], more recently there has been an increasing focus on the use of more moderate (~3-6 mg/kg) caffeine doses 105 
[26]. The success of these trials in turn has prompted research investigating the efficacy of lower doses of 106 
caffeine (≤3 mg/kg). Whilst the number of these trials is relatively low, a recent review by Spriet [24] concluded 107 
that these lower caffeine doses, when consumed prior to exercise, likely enhanced athletic performance. 108 
Similarly, a recent meta-analysis of the ergogenic effects of caffeine-containing energy drinks, the majority of 109 
which had a dose of ≤3 mg/kg, concluded that ingestion of these drinks improved performance [27]. 110 
Accordingly, in general, the evidence to date supports the perspective that lower doses of caffeine are ergogenic 111 
for sports performance, particularly with regards to endurance sport. However, perhaps a more pertinent 112 
consideration for athletes is whether these low doses of caffeine are as effective in enhancing performance as 113 
the more conventional, higher doses? As athletes consume caffeine primarily to improve performance, and 114 
presumably wish to improve their performance to the maximum amount possible, this is an important 115 
consideration. If low doses of caffeine are ergogenic, but not as ergogenic as higher doses, then athletes 116 
consuming these lower doses may be leaving some potential performance improvements on the table. As such, 117 
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the question as to whether or not low (≤3 mg/kg) doses of caffeine exert similar ergogenic effects as more 118 
conventional, moderate (3-6 mg/kg) doses seems highly relevant. 119 
 120 
There are two ways by which we could determine whether low doses of caffeine are as ergogenic as 121 
higher doses. Firstly, we could compare the magnitude of improvements seen between studies; for example, 122 
determining whether the size of the ergogenic effect is greater in those studies that utilise 6 mg/kg compared to 123 
2 mg/kg. This superficially simple approach, however, is surprisingly problematic, because the magnitude of 124 
caffeine-derived performance enhancement is highly variable between both trials and subjects [28]. As 125 
illustration, consider the array of variables which interact to modulate caffeine ergogenesis; genotype 126 
[22,29,30], training status [31], habitual caffeine use [32], sex [33], caffeine source [34], age [35], expectancy 127 
[36], exercise type [37], and time of day of exercise [38]. Given the extensive differences between study 128 
methodologies and recruited populations, it seems unlikely that such a comparison would provide the desired, 129 
and necessary, conceptual clarity.  130 
 131 
Instead, a better option might be to have low-dose and high-dose caffeine trials within each study, 132 
thereby allowing for a direct comparison between the different caffeine doses. Although seemingly sensible, 133 
such an approach is surprisingly uncommon. In a recent review, Spriet [24] concluded that low caffeine doses 134 
(≤3 mg/kg), taken before exercise, enhanced athletic performance compared to placebo. However, the vast 135 
majority of the studies included in Spriet’s [24] review (summarized in table 1) did not directly compare a low 136 
dose (≤3 mg/kg) of caffeine with a higher dose (>3 mg/kg). In fact, only 4 of the 14 studies did so [39-42]. Of 137 
these four, there were mixed results; two reported no additional benefits from 6 mg/kg of caffeine compared to 138 
3mg/kg of caffeine when examining aerobic endurance performance [39,41]; one reported that 4.5 mg/kg 139 
enhanced aerobic endurance performance to a greater extent than 3.2 mg/kg, which in turn was more ergogenic 140 
than a dose of 2.1 mg/kg [40]; and one found that 5 mg/kg enhanced maximum knee flexion and extension 141 
isokinetic torque, whilst 2 mg/kg did not [42]. The remaining studies either did not use a caffeine dose above 3 142 
mg/kg in their comparison [43-45], or only used a single caffeine dose (≤3 mg/kg), and compared this to 143 
placebo [46-52]. We identified additional papers published following Spriet’s [24] review that directly 144 
examined a low versus high dose of caffeine [22,53-56]. Of these, Arazi and colleagues [53] reported no 145 
difference in performance between a low (2 mg/kg) and high (5 mg/kg) caffeine dose—a finding replicated by 146 
Guest and colleagues [22] with doses of 2 and 4 mg/kg on a 10kg cycle ergometer time trial—whilst others [53-147 
 
 
6 
55] reported mixed results, in part because of the large number of performance tests utilised. Interestingly, Sabol 148 
and colleagues [56] reported similar improvements in vertical jump performance following ingestion of 2, 4, 149 
and 6 mg/kg of caffeine, whilst upper body ballistic exercise performance was only enhanced following a dose 150 
of 6 mg/kg. Consequently, due to both the equivocal results of the small numbers of trials directly investigating 151 
this phenomenon, and the lack of higher caffeine doses utilised in other trials, it is unclear whether lower doses 152 
of caffeine are as ergogenic as higher doses. Recently, Talanian & Spriet [57] suggested that, based on their 153 
interpretations of five lower-dose caffeine studies [26,40,43,44,57] that the timing of the lower caffeine dose 154 
may be a crucial aspect, with ingestion less than 60 minutes pre-exercise associated with a greater performance 155 
benefit than later ingestion (80-180 minutes pre-exercise). 156 
 157 
 158 
Study Subjects Caffeine 
Timing 
Exercise Caffeine 
Dose 
Comparison 
to best 
practice? 
Finding 
Graham 
and  
Spriet 
[39] 
8 well-trained 
males 
60 minutes 
pre-
exercise 
TTE run at 
85% 
VO2max  
0 
(placebo), 
3, 6, & 9 
mg/kg 
Yes Endurance was 
equally enhanced 
in both 3 and 6 
mg/kg caffeine 
trials 
Kovacs 
et al. [40] 
15 well-
trained males 
60% of 
solution 60 
minutes 
pre-
exercise, 
and 20% at 
two time 
points 
within 
1-hour 
maximum 
cycle 
0 
(Placebo), 
2.1, 3.2, 
4.5 mg/kg 
Yes Performance was 
enhanced to the 
greatest extent in 
4.5 mg/kg, then 3.2 
mg/kg, then 2.1 
mg/kg. 
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exercise 
trial.  
Jenkins 
et al. [44] 
13 trained 
male cyclists 
60 minutes 
pre-
exercise 
15 minutes 
VO2 peak 
performance 
cycle 
0 
(placebo), 
1, 2, 3 
mg/kg 
No Compared to 
placebo, only 2 
mg/kg significantly 
enhanced 
performance 
Desbrow 
et al. [43] 
9 trained male 
cyclists 
60 minutes 
pre-
exercise 
120 min 
steady state 
cycle, 
followed by 
TT.  
0 
(placebo), 
1.5, 3 
mg/kg 
No No performance 
enhancement with 
caffeine 
Irwin et 
al. [50] 
12 trained 
male cyclists 
90 minutes 
pre-
exercise 
Cycle TT 0 
(placebo) 
or 3 
mg/kg 
No Caffeine enhances 
performance 
compared to 
placebo 
Desbrow 
et al. [41] 
16 trained 
cyclists 
90 minutes 
pre-
exercise 
60 min cycle 
at 75% peak 
sustainable 
power 
0 
(placebo), 
3, 6 
mg/kg 
Yes No additional 
benefit of 6 mg/kg 
compared to 3 
mg/kg 
Wiles et 
al. [46] 
34 male 
athletes 
60 minutes 
pre-
exercise 
1500m run ~150-200 
mg from 
coffee (3g 
total 
coffee) 
No Caffeine enhanced 
performance.  
Van 
Nieuwen
hoven et 
al. [47] 
98 well trained 
male and 
females 
At start, 
4.5, 9 and 
13.5 km of 
exercise 
trial 
18km run 90 mg No No effect of 
caffeine 
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Bridge & 
Jones 
[48] 
8 male runners 60 minutes 
pre-
exercise 
8km race 0 
(Placebo), 
3 mg/kg, 
or no 
suppleme
nt.  
No Caffeine enhanced 
performance. 
Schubert 
et al. [45] 
6 male runners 65 minutes 
pre-
exercise 
5km run TT 0 
(placebo), 
80 mg, 
140 mg) 
No No differences in 
caffeine 
consumption trials 
when compared to 
placebo. 
Perez-
Lopez et 
al. [52] 
13 elite female 
volleyball 
players 
60 minutes 
pre-
exercise 
Volleyball 
specific tests 
0 
(placebo) 
and 3 
mg/kg 
No Caffeine enhanced 
performance.  
Del Coso 
et al. [51] 
15 male 
volleyball 
players 
60 minutes 
pre-
exercise 
Volleyball 
specific tests 
0 
(placebo) 
and 3 
mg/kg 
No Caffeine enhanced 
performance. 
Strecker 
et al. [49] 
10 male tennis 
players 
90 minutes 
pre-
exercise 
Tennis skill 
performance 
0 
(placebo) 
and 3 
mg/kg 
No Caffeine enhanced 
performance.  
Astorino 
et al. [42] 
15 active 
males 
60 minutes 
pre-
exercise 
40 maximal 
knee 
extensions 
0 
(placebo), 
2, 5 
mg/kg 
Yes Only the 5mg/kg 
dose enhanced 
performance.  
Talanian 
& Spriet 
[57] 
15 cyclists 
(n=4 female) 
40 (~42% 
total), 20 
(~33% 
Time to 
completion 
cycle 
0 
(placebo), 
No Higher caffeine 
dose enhanced 
time-trial 
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total) and 0 
(~25%) 
minutes 
pre-time 
trial 
ergometer 
test 
~1.5, ~2.9 
mg/kg 
performance to a 
greater extent than 
lower dose. 
Tallis & 
Yavuz 
[55] 
10 active 
males 
60 minutes 
pre-
exercise 
Isokinetic 
concentric 
and 
eccentric 
strength at 
60 & 180 
deg/s of 
elbow and 
knee flexors 
0 
(placebo), 
3 and 6 
mg/kg 
Yes No effect of 
caffeine on elbow 
flexor (concentric 
and eccentric) or 
knee (eccentric) 
flexor strength. 
Both caffeine 
doses increased 
concentric force in 
knee extensors at 
180 deg/s, with no 
difference between 
doses. Only the 
higher (6 mg/kg) 
dose enhanced 
force during 
repeated 
contractions. 
Turley et 
al. [54] 
26 young (8-
10y) boys 
60 minutes 
pre-
exercise 
Hand grip 
and Wingate 
tests.. 
0, 
(placebo), 
1, 3 and 5 
mg/kg 
Yes Grip strength – 
significantly higher 
in 3 and 5 mg/kg 
caffeine trials.  
Wingate – 3 mg/kg 
produced greatest 
peak power, whilst 
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5 mg/kg produced 
greatest mean 
power.  
Arazi et 
al. [53] 
10 female 
karate athletes 
60 minutes 
pre-
exercise 
1RM leg 
press, leg 
press 
repetitions to 
failure, 
vertical 
jump, RAST 
test.  
0 
(placebo), 
2 and 5 
mg/kg 
Yes No significant 
difference in test 
performance 
between groups.  
Sabol et 
al [56] 
20 
recreationally 
active males 
60 minutes 
pre-
exercise 
Medicine 
ball throw 
and vertical 
jump 
0 
(placebo), 
2, 4, and 6 
mg/kg 
Yes No difference 
between caffeine 
doses in terms of 
lower body 
performance 
enhancement. Only 
6 mg/kg enhanced 
upper body 
performance.  
Guest et 
al [22] 
101 
competitive 
males 
~45 
minutes 
pre-
exercise 
10km cycle 
ergometer 
time trial 
0 
(placebo), 
2 and 4 
mg/kg 
Yes No difference in 
performance 
enhancement 
between caffeine 
doses; both 
enhanced 
performance 
compared to 
placebo.  
TTE – Time-to-exhaustion; VO2max - maximal oxygen consumption; TT – Time Trial 159 
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 160 
Table 1 – A summary of studies examining the impact of low doses of pre-exercise caffeine on sports 161 
performance. For the purposes of this table, a low dose of caffeine is defined as 3mg/kg or less. (Adapted from 162 
Spriet [24]; studies that did not utilise a pre-exercise caffeine dose, or those that only used a caffeine dose 163 
greater than 3mg/kg, were excluded, and additional relevant papers published since that review have been 164 
added). 1RM; one repetition maximum. RAST; running-based anaerobic sprint test.  165 
 166 
3. A potential solution? 167 
 168 
This is not to suggest that these methodological shortcomings are the fault of researchers. Commonly, 169 
investigations are designed to explore phenomena tangentially bordering, but not directly targeting, this 170 
experimental question. However, based on our interpretation of the research, it is clear that, to decisively answer 171 
this question, additional trials that directly compare low caffeine doses with those falling into line with the 172 
currently accepted optimal dose (3-6 mg/kg), are required. Such research would remove much of the existing 173 
ambiguity permeating caffeine research. An equivalent approach is considered best-practice in the realm of 174 
medical drug development, where randomised controlled trials are designed to directly compare new drugs with 175 
the best currently available treatment as the optimal approach [58]. Accordingly, it is not sufficient to 176 
demonstrate that a new intervention is more effective than placebo, but that it produces better results than the 177 
currently accepted best treatment.  178 
 179 
An illustrative example is that of research into caffeinated chewing gum, an increasing popular 180 
ergogenic aid in sport [19]. Studies investigating the ergogenic effects of caffeinated gum on aerobic endurance 181 
performance are currently equivocal. As per a recent review [19]. two studies [59,60] reported no ergogenic 182 
effect of caffeinated gum on aerobic endurance performance, whilst three studies [61-63] reported a positive 183 
effect. An obvious distinction between these trials is the dose; the “no effect” findings occurred following a dose 184 
of 200 mg, whilst the positive effect trials employed a dose of 300 mg. If we assume an average subject mass of 185 
~80 kg, then 200 mg of caffeine would be classed as a low dose, and 300 mg would fall within the 186 
recommended optimal threshold. Here, the inclusion of a trial utilising a currently accepted optimal caffeine 187 
dose in the 200 mg studies would potentially resolve the current ambiguity.  188 
 189 
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Additionally, there is contemporary debate regarding the impact of regular caffeine consumption on the 190 
subsequent ergogenic effects of caffeine, with some studies finding a negative impact of habituation [32], whilst 191 
others report none [64]. One potential outcome is that regular caffeine use requires a subsequently larger 192 
caffeine dose to exert performance benefits [65]. As such, the dose of caffeine used in experimental trials 193 
substantially influences study conclusions, particularly when exploring the effects of habitual use. Recently, 194 
Evans and colleagues [66] explored the influence of caffeinated gum, supplying 200 mg of caffeine, on repeated 195 
sprint performance in team sport athletes. The initial finding was that caffeine did not confer any ergogenic 196 
effects; however, further analysis demonstrated that habitual caffeine use modified the performance 197 
enhancement seen following caffeine ingestion; in this case, very low habitual caffeine users (<40 mg/d) did 198 
exhibit ergogenic effects, whilst more moderate habitual users (>130 mg/d) did not. Such findings may be 199 
interpreted as evidence that habitual use reduced caffeine’s ergogenic effects. However, an obvious question 200 
emerges; what if the dose of caffeine used was within the currently accepted guidelines, as opposed to <3 201 
mg/kg? As this wasn’t explored, the answer remains unclear. Again, this is not an attack on the authors, who 202 
were exploring a different research question, but it nevertheless underscores the point that increasingly robust 203 
conclusions could be inferred from caffeine research if the currently accepted optimal dose was included.  204 
 205 
4. How robust is the currently accepted optimal dose? 206 
 207 
For the purposes of this review, we have defined the currently accepted optimal dose of caffeine as 208 
between 3 and 6 mg/kg. This figure is based on a number of different reviews and positions stands [14,23]. 209 
Furthermore, it is not suggested that there are any additional ergogenic effects associated with a dose above this 210 
[25]. However, there is considerable inter-individual variation in the ergogenic effects of caffeine ingestion [68]. 211 
This phenomenon becomes apparent when caffeine studies report individual subject data. Jenkins et al. [44], for 212 
example, examined the effects of lower caffeine doses (1, 2, and 3 mg/kg) compared to placebo on a 15-minute 213 
maximum cycle. Of the 13 subjects, one did not exhibit an ergogenic effect at any dose, whilst four found 214 
caffeine ergogenic at every dose, but to different extents. Graham and Spriet [39] demonstrated that 9 mg/kg of 215 
caffeine improved time-to-exhaustion in seven subjects, but with the percentage improvements compared 216 
against the placebo trial varying from 105-250%. Neither of these studies utilised the currently accepted optimal 217 
caffeine dose, so whether the findings would have been replicated under those conditions remains unclear. 218 
Nevertheless, the results serve to illustrate the extent of inter-individual responses to caffeine. Furthermore, 219 
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some studies report no ergogenic effect of caffeine [67], again illustrating that the individual response to a 220 
standardised dose of caffeine is highly variable. The drivers of the variation of wide and varied, but can be 221 
grossly summarised as genetic, environmental (i.e. non-genetic), and epigenetic factors [68]. 222 
 223 
4.1 Genetic 224 
 Variation within CYP1A2, the gene encoding for cytochrome P450 1A2—the enzyme responsible for 225 
95% of all caffeine metabolism [69]—has been shown to affect caffeine metabolization speed. Here, individuals 226 
with a C allele metabolise caffeine slower than AA genotypes [70]. Potentially, this single nucleotide 227 
polymorphism (SNP) might impact caffeine ergogenicity, with C allele carriers exhibiting lower [29] or no [22] 228 
ergogenic effects. However, these findings are currently tentative, with other studies reporting the opposite [71], 229 
or no effect [72] of this polymorphism on performance. The mechanism underpinning this reduced ergogenic 230 
effect in C allele carriers is currently unclear. Guest and colleagues [22] suggest that, because caffeine is a 231 
vasoconstrictor, slow metabolisers experience this vasoconstriction for a longer period of time, inhibiting the 232 
delivery of oxygen and nutrients to the working muscle. Conversely, Womack and colleagues [29] suggest that 233 
the downstream metabolites of caffeine (paraxanthine, theobromine, and theophylline) confer their own 234 
ergogenic effect; in this case, the presence of these metabolites would be lower in C allele carriers than AA 235 
genotypes at a given time point due to the slower metabolization of caffeine. As such, it’s not clear whether 236 
caffeine has a reduced ergogenic, or even an ergolytic, effect in C allele carriers, or whether they need to ingest 237 
caffeine a greater amount of time before exercise [73]. Similarly, there is the potential that a SNP in ADORA2A, 238 
which encodes for a sub-type of adenosine receptor, may underpin some of the individual variation in response 239 
to caffeine, in terms of ergogenicity [30], anxiety [74], and sleep disturbances [75].  240 
 241 
4.2 Environmental 242 
Alongside these genetic drivers are environmental determinants of individual variation in the response 243 
to caffeine, which include age [35], training status [31], habitual caffeine use [32,65], diet [76], medication use 244 
[77], and personal belief as to whether caffeine enhances performance [36].  245 
 246 
4.3 Epigenetics 247 
Habitual caffeine use likely induces long-term epigenetic changes [78,79], which may in turn affect 248 
future ergogenic effects, potentially by increasing caffeine metabolization speed [80]. For example, habitual 249 
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caffeine use increases CYP1A2 activity [81], thereby increasing caffeine clearance, which may alter the 250 
expected ergogenic effects of caffeine ingestion. Additionally, long-term exposure to caffeine may alter its 251 
stimulatory effects, partly mediated by inhibition of genes affecting the adenosine pathway [82].  252 
 253 
Accordingly, whilst caffeine is ergogenic, the currently accepted optimal caffeine dose may not be 254 
optimal for everyone [68]. Some individuals may benefit from lower doses of caffeine (discussed below), whilst 255 
others may need higher doses. Nevertheless, at present the abundance of evidence does suggest that, for most 256 
people, most of the time, a caffeine dose of between 3-6 mg/kg likely is sufficient to realise the optimum 257 
ergogenic effects. Indeed, Burke [83] suggested that the dose-response relationship of caffeine on performance 258 
appears to plateau at around 3 mg/kg. As such, this dose may represent a target threshold to maximise caffeine’s 259 
ergogenic effects, although higher doses are indeed ergogenic, and in some cases may be required, such as in 260 
habitual users [65]. Sensibly, the recommendations of 3-6 mg/kg should be taken as a starting point, from which 261 
individual experimentation can be used to refine pre-training and pre-competition caffeine strategies. 262 
 263 
5. When might lower doses of caffeine be more appropriate? 264 
 265 
 The purpose of this article is not to discount the ergogenic potential of lower doses of caffeine; indeed, 266 
available evidence suggests that these lower doses can enhance performance [24]. Furthermore, the use of lower 267 
doses of caffeine may be preferential in certain situations. Higher doses of caffeine, for example, appear to be 268 
more likely to induce negative side-effects, such as anxiety [84] and sleep disturbances [85]. From a sporting 269 
perspective, both of these outcomes have the potential to negatively impact performance [86,87]. Furthermore, 270 
sleep disturbances following caffeine ingestion may reduce recovery from exercise and/or competition, and 271 
subsequently harm physical performance the following day [87]. In these cases, individual athletes need to make 272 
informed, strategic decisions negotiating the trade-off between the optimised ergogenic effects seen with higher 273 
doses of caffeine against the potential for increased anxiety or compromised sleep. Here, the context is critical; 274 
arguably, the athlete would be more concerned with sleep disturbances if there is a high priority competitive 275 
bout in the proceeding few days, such as during the heats at the Olympic Games, as opposed to an Olympic 276 
Final, when no subsequent performance is required. Conversely, athletes predisposed to greater pre-competition 277 
anxiety may wish to consume less caffeine prior to important competitions than they would for lower level 278 
competitions and training, as caffeine may exacerbate this anxiety-promoting predisposition. 279 
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 280 
 Similarly, differences in genotype may predispose individuals to respond well to lower doses of 281 
caffeine. Preliminary evidence suggests, for example, that moderate doses of caffeine (4 mg/kg) are harmful to 282 
endurance performance in CYP1A2 genotypes [22]. However, a dose of 2 mg/kg showed no performance 283 
decrement, suggesting that lower doses for these individuals may be more favourable than higher doses. Whilst 284 
further clarification is required, the potential for genetically-guided caffeine recommendations to be made, with 285 
certain genotypes potentially responding better to lower caffeine doses, remains a future possibility [68,73]. 286 
 287 
 Regular ingestion of lower doses of caffeine may also guard against habituation to higher doses, which 288 
has been shown to negatively affect the ergogenic benefits of a caffeine dose [32,65], although this remains 289 
equivocal [64]. There is the potential that regular ingestion of caffeine increases the amount of caffeine required 290 
to realise the ergogenic effects, such that if an athlete habitually consumed 3 mg/kg of caffeine pre-training, 291 
they might require a caffeine dose closer to 6 mg/kg pre-competition [65]. This may increase the potential for 292 
adverse side effects, and, if the habitual dose increases over time, might take the athlete to a point in which 293 
further increases in dose don’t restore the optimised ergogenic effect of caffeine. In this scenario, habitual use of 294 
lower caffeine doses (~3 mg/kg) may facilitate an increased pre-competition dose, thereby allowing for both 295 
enhancement of regular training, along with competition performance.  296 
 297 
6. Conclusions 298 
 299 
In summary, the existing research is clear that low doses of caffeine are ergogenic [24]. However, to 300 
derive more robust conclusions there is an evident need within these studies for a direct comparison with the 301 
currently accepted optimal caffeine dose (>3 to 6 mg/kg). The majority of studies that support the ergogenic 302 
benefits of low doses of caffeine do not compare these low doses to the caffeine doses more typically considered 303 
to be ergogenic. As a result, whilst low doses of caffeine do offer a performance benefit, it’s not clear that this 304 
performance benefit is greater than, or indeed equal to, that offered by caffeine doses between 3 and 6 mg/kg. 305 
The addition of a caffeine trial utilising 3-6 mg/kg of caffeine would therefore greatly aid in the interpretation of 306 
such findings, and so should be considered in future research.   307 
 308 
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 We hope that the points raised here enable athletes, coaches, support staff, and perhaps even 309 
researchers to better critique the studies underpinning their caffeine strategies and recommendations. Moving 310 
forward, we also recommend that caffeine researchers include a trial that utilizes the currently accepted optimal 311 
dose of caffeine – even if this dose is not optimal for everyone – in order to enable more direct comparisons 312 
between studies, and thereby enabling firmer conclusions to be made. Finally, as per our previous explorations 313 
of caffeine use in sport [65,68], we urge athletes and practitioners to experiment with different caffeine doses, 314 
timing, and ingestion methods in order to uncover the strategies best suiting their unique genetic predispositions, 315 
environmental influences, and individual histories. 316 
 317 
Novelty Statement & Practical Applications 318 
This critical review has demonstrated that, whilst lower doses (3 mg/kg) of caffeine have the potential to be 319 
ergogenic, it’s not clear whether such doses are as ergogenic as higher doses. The main cause of this uncertainty 320 
is due to a lack of trials directly comparing low and high doses of caffeine. As such, athletes, coaches and 321 
practitioners looking to utilise caffeine as a means to enhance performance would be best placed to experiment 322 
with various different caffeine doses in order to determine the optimal dose to enhance their performance, given 323 
their own unique biology, history, and performance requirements.  324 
 325 
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